China Ophthalmic Drugs Market: How Is Anti-VEGF Therapy Dominating the Value Segment?

Anti-VEGF intravitreal therapy — the ranibizumab (Lucentis), aflibercept (Eylea), conbercept (Kang Bai Xi), and brolucizumab (Beovu) injectable treatments for wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion — creates the highest-value commercial segment in the Chinese ophthalmic drugs market, with the China Ophthalmic Drugs Market reflecting anti-VEGF as the commercial anchor generating the majority of market revenue from premium intravitreal injection pricing.

Conbercept China domestic commercial success — the Chengdu Kanghong Pharmaceutical's conbercept (康柏西普) achieving NMPA approval and NRDL inclusion creating the first domestically developed anti-VEGF agent in China. Conbercept's dramatically lower pricing than Lucentis and Eylea following NRDL negotiation creating the commercial model where domestic anti-VEGF expanded treatment access while reducing per-injection revenue for all brands.

VBP potential for intravitreal agents — the NHSA's consideration of extending volume-based procurement to biological drugs including anti-VEGF agents creating the commercial uncertainty in this premium segment. The precedent from biosimilar insulin VBP creating the anticipation of significant price reduction if anti-VEGF included in VBP rounds.

Anti-VEGF treatment frequency commercial dynamics — the Chinese ophthalmologist's typical three to five injection per year treatment intensity (versus six to eight in Western practice) from resource constraints and patient financial burden creating the commercial reality that Chinese per-patient anti-VEGF revenue is significantly below Western markets.

Do you think Chinese anti-VEGF biosimilars will achieve market approval and create additional price competition in this already commercially pressured segment?

FAQ

What anti-VEGF drugs are approved in China? China anti-VEGF market: ranibizumab (Lucentis, Novartis/Roche): first approved; wet AMD; DME; RVO; approximately RMB 5,000-7,000/injection before NRDL; post-NRDL approximately RMB 2,000-3,000; aflibercept (Eylea, Bayer): approved; wet AMD; DME; RVO; similar pricing trajectory; conbercept (康柏西普, Kanghong): first Chinese domestic anti-VEGF; NRDL included; lower pricing approximately RMB 1,500-2,500; significant market share gain; brolucizumab (Beovu, Novartis): approved; wet AMD; Q12W dosing advantage; bevacizumab (off-label Avastin): used off-label at significantly lower cost; biosimilars: multiple ranibizumab biosimilars in development; NMPA review; combined: anti-VEGF market approximately RMB 5-8 billion; largest ophthalmic segment by value.

How does NRDL impact anti-VEGF commercial dynamics in China? Anti-VEGF NRDL commercial impact: NRDL negotiation: NHSA annual negotiation dramatically reducing prices; ranibizumab: approximately sixty to seventy percent price reduction; aflibercept: similar reduction; conbercept: already domestic pricing; NRDL impact: dramatically increased patient access (previously only wealthy or insured could afford); hospital formulary inclusion; prescription volume increase significantly post-NRDL; commercial paradox: lower price → higher volume → net revenue uncertain; analysis: most anti-VEGF manufacturers seeing net revenue maintained or growing from volume increase compensating price cut; access improvement: NRDL enabling treatment of patients previously untreated; unmet need reduction; ophthalmology practice: anti-VEGF service volume increasing from NRDL access; ophthalmologists performing more injections; overall: NRDL transforming Chinese AMD and DME treatment from elite to mainstream therapy.

#ChinaOphthalmic #AntiVEGF #WetAMD #ConbercepChina #LucentisChina #IntravitrealChina